The impact of vitamin D supplementation on sudden sensorineural hearing loss in vitamin D deficient patients: A double-blind, placebo-controlled trial: A pilot study.

Vitamin D supplementation led to significantly greater hearing improvement at 2000 Hz and 4000 Hz frequencies compared to placebo.

• P = 0.004 for 2000 Hz and P = 0.001 for 4000 Hz
• These frequencies are described as 'critical for speech perception'
• Both groups received routine corticosteroid treatment; the intervention group additionally received 50,000 IU vitamin D3 (Pearl formulation)
• Assessments were conducted at baseline, 10 days, and 30 days post-treatment

No significant benefits of vitamin D supplementation were observed at lower frequencies (500 Hz and 1000 Hz) or at 6000 Hz.

• At 6000 Hz, the control group showed greater improvement than the intervention group
• No significant differences between groups were found at 500 Hz or 1000 Hz
• Both groups showed significant overall hearing improvement at one month

Both groups exhibited significant hearing improvement at one month following treatment.

• Outcomes measured included pure-tone average (PTA) at 500, 1000, 2000, 4000, and 6000 Hz, speech reception threshold (SRT), and speech discrimination score (SDS)
• Baseline demographic, biochemical, and audiological characteristics showed no significant differences between groups
• The control group received routine corticosteroid treatment plus placebo

Vitamin D levels significantly increased in the intervention group without affecting serum phosphorus or calcium concentrations.

• Intervention group received 50,000 IU vitamin D3 (Pearl) in addition to standard corticosteroid treatment
• Eligible patients had serum vitamin D levels less than 50 nmol/L or 20 ng/mL at baseline
• No significant changes in serum phosphorus or calcium were observed, suggesting the supplementation dose was safe in this context

The study enrolled vitamin D deficient SSNHL patients with SSNHL occurring within 45 days prior to the study.

• This was a randomized, double-blind, placebo-controlled pilot study
• Inclusion criterion for vitamin D deficiency was serum vitamin D levels less than 50 nmol/L or 20 ng/mL
• Patients were divided into an intervention group (corticosteroid + vitamin D3 50,000 IU) and a control group (corticosteroid + placebo)
• The study rationale was based on 'the high prevalence of vitamin D deficiency among sudden sensorineural hearing loss (SSNHL) patients'